Position in CLYM
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,959,963
+$1,685,623 QoQ
Shares Held
286,126
+109.6% QoQ
Ownership
0.498%
of shares outstanding
% of Portfolio
0.91%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CLYM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DIADEMA PARTNERS LP holds $217,374,297 across 66 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
139,218 | $26,072,747 | |
| 2 | ABVX |
Abivax S.A.
|
163,644 | $21,807,199 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
493,664 | $19,104,796 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
312,846 | $17,901,048 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
441,808 | $17,234,930 | |
| 6 | EWTX |
Edgewise Therapeutics, Inc.
|
272,214 | $11,060,054 | |
| 7 | KOD |
Kodiak Sciences Inc.
|
218,117 | $8,497,838 | |
| 8 | IMCR |
Immunocore Holdings plc
|
254,863 | $8,091,900 |
All Filings in CLYM
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,959,963 | 286,126 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $274,340 | 136,488 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $870,647 | 702,135 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $817,159 | 669,803 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $673,961 | 374,423 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||